#### UNIVERSITÀ DELLA CALABRIA

#### DIPARTIMENTO DI MATEMATICA E INFORMATICA

Via P. Bucci, Cubo 30B 87036 Rende (CS) – ITALIA

2023 May 11th





Bayesian (Causal) networks for Healthcare, Medicine and Biology

Fabio Stella University of Milan-Bicocca Department of Informatics, Systems and Communication

#### Summary

- Machine Learning
- The Story Behind the Data
- The Ladder of Causation
- Bayesian (causal) networks
- Healthcare, Medicine and Biology





Bayesian (Causal) networks for Healthcare, Medicine and Biology

Fabio Stella University of Milan-Bicocca Department of Informatics, Systems and Communication

— an ongoing revolution —

## Reinforcement Learning

- Learn by interacting with the environment
- The environment reacts to our decisions/actions
- Sequential learning, only at the end of the game we know our performance (reward/punishment)

OD:20:49

## 2016: World Go Champion Beaten by Deep Learning

Google DeepMind

Challenge Match

#### At last – a computer program that can beat a champion Go player PAGE484 ALL SYSTEMS GO


nature

CONCEPTION SONGBIRDS A LA CARTE llegal harvestof millions of Mediterraneen birds Ref. 62

SAFEGUARD TRANSPARENCY Don't let operness backgire on individuals meets


VHEN GENES WHEN GENES COT 'SELFISH' Duwkins's calling cand di warson

 Many different names for learning




## But most of machine learning nowadays is just curve fitting

Curve fitting
 (correlations) - linear



Curve fitting - nonlinear



Deep Neural Networks



## Highly dimensional, highly nonlinear

curve fitting

#### For Cancer Risk, a Bottle of Wine Equals This Many Cigarettes

By Rachael Rettner March 28, 2019 Health

() C) 🚳 () C) C)



NEWS Moderate Wine Drinkers Live Longer, Study Shows NSW fires

The debate over alcohol and health gets a positive boost from a detaile older Americans



Inealth Food Fitness Wellness Parenting Vital Signs

By Katie Hunt, CNN

Could coffee help you lose weight? New research suggests a fat-busting effect



Is coffee a health food? 01:06

California says coffee contains carcinogenic chemical, but doesn't have to be labelled as carcinogenic

Updated 4 Jun 2019, 3:29pm

Print

California has officially given its blessing to coffee, declaring the beverage does not pose a "significant" cancer risk despite containing a chemical listed by the state as being carcinogenic.

The official ruling, proposed a year ago and confirmed on Monday (local time), came in response to a Los Angeles judge ruling Starbucks and other companies failed to show that benefits from drinking coffee outweighed risks from a byproduct of the roasting process

The judge's ruling put the industry in jeopardy of hefty civil penalties and in the position of either



PHOTO: Roasted coffee beans contain acrylamide - a



Pay My Bill

| HEART | MIND &<br>MOOD | PAIN | STAYING<br>HEALTHY | CANCER | DISEASES |
|-------|----------------|------|--------------------|--------|----------|
|       |                |      | 3                  |        | - C-     |

Home » Harvard Health Blog » E-cigarettes: Good news, bad news - Harvard Health Blog

#### E-cigarettes: Good news, bad news

POSTED JULY 25, 2016, 9:30 AM , UPDATED AUGUST 05, 2019, 11:33 AM



Follow me at @JohnRossMD

Americans are confused about electronic cigarettes A recent poll showed that the public was about

CM health Food Fitness Wellness Parenting Vital Signs

#### Daily or high-potency cannabis increases risk of psychotic disorder, study finds

By Susan Scutti, CNN () Updated 2331 GMT (0731 HKT) March 19, 2019



Does marijuana lead to increase in mental illness? 03:42



his is the Ca where Felicity

ver 2.000 p remains found deceased.






Spurious Correlations




# Fitting can be highly misleading



**Spurious Correlations** 


# An elementary problem (or not?)

- The way we collect and aggregate data matters a lot but being acknowledged is not enough to learn from data alone
- No matter how many (observational) data are available, we will never know which is the true story



#### Causation is the key

- What we (computers so far) miss is causal knowledge for predicting the consequences of actions
- Causation for us is a synonym of understanding
- Actual intelligence needs causal knowledge
- But causal knowledge is not in the data!



# The Story Behind the Data

— why causality matters? —

- Named after Edward Simpson (born 1922)
- A group of sick patients are given the option to try a new drug
- Among those who took the drug, a lower percentage recovered than among those who did not
- However, when we partition by gender, we see that:
  - *more* men taking the drug recover than do men are not taking the drug, and
  - more women taking the drug recover than do women are not taking the drug!



The drug appears to help men and women, but hurts the general population





- Named after Edward Simpson (born 1922)
- A group of sick patients are given the option to try a new drug
- Among those who took the drug, a lower percentage recovered than among those who did not
- However, when we partition by gender, we see that:
  - *more* men taking the drug recover than do men are not taking the drug, and
  - more women taking the drug recover than do women are not taking the drug!

**Example 1.2.1** We record the recovery rates of 700 patients who were given access to the drug. A total of 350 patients chose to take the drug and 350 patients did not. The results of the study are shown in **Table 1.1**.

| Table 1.1 Results of a study into a new drug, with gender being taken into account |          |           |             |  |          |           |             |  |  |  |
|--|----------|-----------|-------------|--|----------|-----------|-------------|--|--|--|
|  | Drug     |           |             |  | No Drug  |           |             |  |  |  |
|  | patients | recovered | % recovered |  | patients | recovered | % recovered |  |  |  |
| Men  | 87       | 81        | 93%         |  | 270      | 234       | 87%         |  |  |  |
| Women  | 263      | 192       | 73%         |  | 80       | 55        | 69%         |  |  |  |
| Combined data  | 350      | 273       | 78%         |  | 350      | 289       | 83%         |  |  |  |

- Named after Edward Simpson (born 1922)
- A group of sick patients are given the option to try a new drug
- Among those who took the drug, a lower percentage recovered than among those who did not
- However, when we partition by gender, we see that:
  - *more* men taking the drug recover than do men are not taking the drug, and
  - more women taking the drug recover than do women are not taking the drug!

**Example 1.2.1** We record the recovery rates of 700 patients who were given access to the drug. A total of 350 patients chose to take the drug and 350 patients did not. The results of the study are shown in **Table 1.1**.

**Table 1.1** Results of a study into a new drug, with gender being taken into account

|               |          | Drug      |             | No Drug  |           |             |  |
|---------------|----------|-----------|-------------|----------|-----------|-------------|--|
|               | patients | recovered | % recovered | patients | recovered | % recovered |  |
| Men           | 87       | 81        | 93%         | 270      | 234       | 87%         |  |
| Women         | 263      | 192       | 73%         | 80       | 55        | 69%         |  |
| Combined data | 350      | 273       | 78%         | 350      | 289       | 83%         |  |

Drug vs non-drug takers recovery rates:

93% vs 87% male

(the drug helps)

- Named after Edward Simpson (born 1922)
- A group of sick patients are given the option to try a new drug
- Among those who took the drug, a lower percentage recovered than among those who did not
- However, when we partition by gender, we see that:
  - *more* men taking the drug recover than do men are not taking the drug, and
  - more women taking the drug recover than do women are not taking the drug!

**Example 1.2.1** We record the recovery rates of 700 patients who were given access to the drug. A total of 350 patients chose to take the drug and 350 patients did not. The results of the study are shown in **Table 1.1**.

**Table 1.1** Results of a study into a new drug, with gender being taken into account

|               |          | Drug      |             | No Drug  |           |             |  |
|---------------|----------|-----------|-------------|----------|-----------|-------------|--|
|               | patients | recovered | % recovered | patients | recovered | % recovered |  |
| Men           | 87       | 81        | 93%         | 270      | 234       | 87%         |  |
| Women         | 263      | 192       | 73%         | 80       | 55        | 69%         |  |
| Combined data | 350      | 273       | 78%         | 350      | 289       | 83%         |  |

Drug vs non-drug takers recovery rates:

73% vs 69% female (the drug helps)

- Named after Edward Simpson (born 1922)
- A group of sick patients are given the option to try a new drug
- Among those who took the drug, a lower percentage recovered than among those who did not
- However, when we partition by gender, we see that:
  - *more* men taking the drug recover than do men are not taking the drug, and
  - more women taking the drug recover than do women are not taking the drug!

**Example 1.2.1** We record the recovery rates of 700 patients who were given access to the drug. A total of 350 patients chose to take the drug and 350 patients did not. The results of the study are shown in **Table 1.1**.

**Table 1.1** Results of a study into a new drug, with gender being taken into account

|               |          | Drug      |             | No Drug  |           |             |
|---------------|----------|-----------|-------------|----------|-----------|-------------|
|               | patients | recovered | % recovered | patients | recovered | % recovered |
| Men           | 87       | 81        | 93%         | 270      | 234       | 87%         |
| Women         | 263      | 192       | 73%         | 80       | 55        | 69%         |
| Combined data | 350      | 273       | 78%         | 350      | 289       | 83%         |

Drug vs non-drug takers recovery rates:

• 78% vs 83% general population!

(the drug hurts) ???

- Named after Edward Simpson (born 1922)
- A group of sick patients are given the option to try a new drug
- Among those who took the drug, a lower percentage recovered than among those who did not
- However, when we partition by gender, we see that:
  - *more* men taking the drug recover than do men are not taking the drug, and
  - more women taking the drug recover than do women are not taking the drug!

**Example 1.2.1** We record the recovery rates of 700 patients who were given access to the drug. A total of 350 patients chose to take the drug and 350 patients did not. The results of the study are shown in **Table 1.1**.

**Table 1.1** Results of a study into a new drug, with gender being taken into account

|                      | Drug     |           |             |  | No Drug  |           |             |
|----------------------|----------|-----------|-------------|--|----------|-----------|-------------|
|                      | patients | recovered | % recovered |  | patients | recovered | % recovered |
| Men                  | 87       | 81        | 93%         |  | 270      | 234       | 87%         |
| Women                | 263      | 192       | 73%         |  | 80       | 55        | 69%         |
| <b>Combined data</b> | 350      | 273       | 78%         |  | 350      | 289       | 83%         |

Drug vs non-drug takers recovery rates:

- 93% vs 87% male
- 73% vs 69% female
- 78% vs 83% general population!

Should a doctor prescribe the drug; to whom?

Should a policy maker approve the drug for use?



#### Understand the causal story behind the data

- What mechanism generated the data?
- Suppose: estrogen has a negative effect on recovery
  - Women less likely to recover than men, regardless of the drug

From the data:

| Table 1.1 Results of a study into a new drug, with gender being taken into account |          |           |             |  |          |           |             |  |  |  |
|--|----------|-----------|-------------|--|----------|-----------|-------------|--|--|--|
|  | Drug     |           |             |  | No Drug  |           |             |  |  |  |
|  | patients | recovered | % recovered |  | patients | recovered | % recovered |  |  |  |
| Men  | 87       | 81        | 93%         |  | 270      | 234       | 87%         |  |  |  |
| Women  | 263      | 192       | 73%         |  | 80       | 55        | 69%         |  |  |  |
| Combined data  | 350      | 273       | 78%         |  | 350      | 289       | 83%         |  |  |  |

#### **Conclusion**: the drug appears to be harmful but it is not

- If we select a drug taker at random, that person is more likely to be a woman
- Hence less likely to recover than a random person who doesn't take the drug

#### **Causal Story**

- Being a woman is a common cause of both drug taking and failure to recover.
- To assess the effectiveness we need to compare subjects of the same gender.

(Ensures that any difference in recovery rates is not ascribable to estrogen)

- We have solved the problem using gender-segregated data
- Then let's just segregate the data whenever possible, right?

#### WRONG!!!

- Consider a drug affecting recovery by lowering blood pressure (BP)
- Unfortunately, it has also a toxic effect

Table 1.2 Results of a study into a new drug, with posttreatment blood pressure taken into account

|               | No Drug  |           |             | Drug     |           |             |  |
|---------------|----------|-----------|-------------|----------|-----------|-------------|--|
|               | patients | recovered | % recovered | patients | recovered | % recovered |  |
| Low BP        | 87       | 81        | 93%         | 270      | 234       | 87%         |  |
| High BP       | 263      | 192       | 73%         | 80       | 55        | 69%         |  |
| Combined data | 350      | 273       | 78%         | 350      | 289       | 83%         |  |

Should a doctor prescribe this drug or not?

- We have solved the problem using gender-segregated data
- Then let's just segregate the data whenever possible, right?

#### WRONG!!!

- Consider a drug affecting recovery by lowering blood pressure (BP)
- Unfortunately, it has also a toxic effect

Table 1.2 Results of a study into a new drug, with posttreatment blood pressure taken into account

|               |          | No Drug   |             | Drug     |           |             |
|---------------|----------|-----------|-------------|----------|-----------|-------------|
|               | patients | recovered | % recovered | patients | recovered | % recovered |
| Low BP        | 87       | 81        | 93%         | 270      | 234       | 87%         |
| High BP       | 263      | 192       | 73%         | 80       | 55        | 69%         |
| Combined data | 350      | 273       | 78%         | 350      | 289       | 83%         |

Should a doctor prescribe this drug or not?

Once again, the answer follows from the way the data were generated.

- We have solved the problem using gender-segregated data
- Then let's just segregate the data whenever possible, right?

#### WRONG!!!

- Consider a drug affecting recovery by lowering blood pressure (BP)
- Unfortunately, it has also a toxic effect

Table 1.2 Results of a study into a new drug, with posttreatment blood pressure taken into account

|               |          | No Drug   |             | Drug     |           |             |  |
|---------------|----------|-----------|-------------|----------|-----------|-------------|--|
|               | patients | recovered | % recovered | patients | recovered | % recovered |  |
| Low BP        | 87       | 81        | 93%         | 270      | 234       | 87%         |  |
| High BP       | 263      | 192       | 73%         | 80       | 55        | 69%         |  |
| Combined data | 350      | 273       | 78%         | 350      | 289       | 83%         |  |

Should a doctor prescribe this drug or not?

Once again, the answer follows from the way the data were generated.

 In the general population, the drug might improve recovery rates because of its effect on blood pressure.

- We have solved the problem using gender-segregated data
- Then let's just segregate the data whenever possible, right?

#### WRONG!!!

- Consider a drug affecting recovery by lowering blood pressure (BP)
- Unfortunately, it has also a toxic effect

 Table 1.2 Results of a study into a new drug, with posttreatment blood pressure taken into account

|                      |          | No Drug   |             | Drug     |           |             |  |
|----------------------|----------|-----------|-------------|----------|-----------|-------------|--|
|                      | patients | recovered | % recovered | patients | recovered | % recovered |  |
| Low BP               | 87       | 81        | 93%         | 270      | 234       | 87%         |  |
| High BP              | 263      | 192       | 73%         | 80       | 55        | 69%         |  |
| <b>Combined data</b> | 350      | 273       | 78%         | 350      | 289       | 83%         |  |

Should a doctor prescribe this drug or not?

Once again, the answer follows from the way the data were generated.

- In the general population, the drug might improve recovery rates because of its effect on blood pressure.
- in subpopulations—the group of people whose posttreatment BP is high and the group whose posttreatment BP is low—we, of course, would not see that effect; we would only see the drug's toxic effect.

- We have solved the problem using gender-segregated data
- Then let's just segregate the data whenever possible, right?

#### WRONG!!!

- Consider a drug affecting recovery by lowering blood pressure (BP)
- Unfortunately, it has also a toxic effect

Table 1.2 Results of a study into a new drug, with posttreatment blood pressure taken into account

|                      |          | No Drug   |             | Drug     |           |             |  |
|----------------------|----------|-----------|-------------|----------|-----------|-------------|--|
|                      | patients | recovered | % recovered | patients | recovered | % recovered |  |
| Low BP               | 87       | 81        | 93%         | 270      | 234       | 87%         |  |
| High BP              | 263      | 192       | 73%         | 80       | 55        | 69%         |  |
| <b>Combined data</b> | 350      | 273       | 78%         | 350      | 289       | 83%         |  |

Should a doctor prescribe this drug or not?

Once again, the answer follows from the way the data were generated.

- In the general population, the drug might improve recovery rates because of its effect on blood pressure.
- in subpopulations—the group of people whose posttreatment BP is high and the group whose posttreatment BP is low—we, of course, would not see that effect; we would only see the drug's toxic effect.

- We have solved the problem using gender-segregated data
- Then let's just segregate the data whenever possible, right?

#### WRONG!!!

- Consider a drug affecting recovery by lowering blood pressure (BP)
- Unfortunately, it has also a toxic effect

Table 1.2 Results of a study into a new drug, with posttreatment blood pressure taken into account

|               |          | No Drug   |             |          | Drug      |             |
|---------------|----------|-----------|-------------|----------|-----------|-------------|
|               | patients | recovered | % recovered | patients | recovered | % recovered |
| Low BP        | 87       | 81        | 93%         | 270      | 234       | 87%         |
| High BP       | 263      | 192       | 73%         | 80       | 55        | 69%         |
| Combined data | 350      | 273       | 78%         | 350      | 289       | 83%         |

Should a doctor prescribe this drug or not? **YES** 

- Only by BP-segregating the data we can see the toxic effect
- It makes no sense to segregate the data; we should use the combined data

- We have solved the problem using gender-segregated data
- Then let's just segregate the data whenever possible, right?

#### WRONG!!!

- Consider a drug affecting recovery by lowering blood pressure (BP)
- Unfortunately, it has also a toxic effect

| Table 1.1 Results of a study into a new drug, with gender being taken into account |                                |     |     |          |           |             |     |  |  |
|--|--------------------------------|-----|-----|----------|-----------|-------------|-----|--|--|
|  | Drug                           |     |     |          |           | No Dru      | 86  |  |  |
|  | patients recovered % recovered |     |     | patients | recovered | % recovered |     |  |  |
| Men  | 87                             | 81  | 93% |          | 270       | 234         | 87% |  |  |
| Women  | 263                            | 192 | 73% |          | 80        | 55          | 69% |  |  |
| Combined data  | 350                            | 273 | 78% |          | 350       | 289         | 83% |  |  |

Table 1.2 Results of a study into a new drug, with posttreatment blood pressure taken into account

|               |          | No Drug   |             |          | Drug      |             |
|---------------|----------|-----------|-------------|----------|-----------|-------------|
|               | patients | recovered | % recovered | patients | recovered | % recovered |
| Low BP        | 87       | 81        | 93%         | 270      | 234       | 87%         |
| High BP       | 263      | 192       | 73%         | 80       | 55        | 69%         |
| Combined data | 350      | 273       | 78%         | 350      | 289       | 83%         |

Should a doctor prescribe this drug or not? **YES** 

- Only by BP-segregating the data we can see the toxic effect
- It makes no sense to segregate the data; we should use the combined data

Note that the data are the same of Simpson's Paradox.


# The Ladder of Causation — How to climb it —



JUDEA PEARL winner of the turing award AND DANA MACKENZIE


# THE BOOKOF WHY

THE NEW SCIENCE OF CAUSE AND EFFECT



# The Ladder of Causation

**Seeing;** we are looking for regularities in observations.




### "What if I see ...?"

Calls for predictions based on passive observations.

It is characterized by the question "What if I see ...?"


For instance, imagine a medical doctor asking,

#### "What does a symptom tell me about a disease?"



### Intervention; ranks higher than association because it involves not just seeing but changing what is.





### "What if do ...?" & "How?"

We step up to the next level of causal queries when we begin to change the world. A typical question for this level is

"Does the patient recover whether I prescribe a given drug?"

|   | ( | 2. INTER   | /ENTION  |
|---|---|------------|--|
|   |   | ACTIVITY:  | Doing, Intervening   |
| _ |   | QUESTIONS: | What if I do? How?<br>(What would Y be if I do X?<br>How can I make Y happen?) |
|   |   | EXAMPLES:  | If I take aspirin, will my headache be cured?<br>What if we ban cigarettes?    |


This already calls for a new kind of knowledge, absent from the data, which we find at rung two of the Ladder of Causation, **Intervention**.

Many scientists have been quite traumatized to learn that none of the methods they learned in statistics is sufficient even to articulate, let alone answer, a simple question like


"Does the patient recover whether I prescribe a given drug?"

#### Counterfactuals; ranks

higher than intervention because it involves **imagining**, **retrospection** and **understanding**.







## "What if I had done ...?" & "Why?"

We might wonder, My headache is gone now, but

- Why?
- Was it the aspirin I took?
- The food I ate?
- The good news I heard?

These queries take us to the top rung of the Ladder of Causation, the level of **Counterfactuals**, because to answer them we must go back in time, change history, and ask,


## "What would have happened if I had not taken the aspirin?"

No experiment in the world can deny treatment to an already treated person and compare the two outcomes, so we must import a whole new kind of knowledge.

# Bayesian (causal) Networks — basic definitions —

#### **Bayesian Networks**

- We want a representation and reasoning system that is based on conditional (and marginal) independence
  - Compact yet expressive representation
  - Efficient reasoning procedures
- Bayesian Networks are such representation
  - Named after Thomas Bayes
  - Term coined in 1985 by Judea Pearl
  - Their invention changed the primary focus of AI from logic to probability




- Named after Edward Simpson (born 1922)
- A group of sick patients are given the option to try a new drug
- Among those who took the drug, a lower percentage recovered than among those who did not
- However, when we partition by gender, we see that:
  - more men taking the drug recover than do men are not taking the drug, and
  - more women taking the drug recover than do women are not taking the drug!


#### Table 1.1 Results of a study into a new drug, with gender being taken into account

|               | Drug     |           |             |  | No Drug  |           |             |  |
|---------------|----------|-----------|-------------|--|----------|-----------|-------------|--|
|               | patients | recovered | % recovered |  | patients | recovered | % recovered |  |
| Men           | 87       | 81        | 93%         |  | 270      | 234       | 87%         |  |
| Women         | 263      | 192       | 73%         |  | 80       | 55        | 69%         |  |
| Combined data | 350      | 273       | 78%         |  | 350      | 289       | 83%         |  |

Table 1.2 Results of a study into a new drug, with posttreatment blood pressure taken into account

|               |          | No Drug   |             |          | Drug      |             |
|---------------|----------|-----------|-------------|----------|-----------|-------------|
|               | patients | recovered | % recovered | patients | recovered | % recovered |
| Low BP        | 87       | 81        | 93%         | 270      | 234       | 87%         |
| High BP       | 263      | 192       | 73%         | 80       | 55        | 69%         |
| Combined data | 350      | 273       | 78%         | 350      | 289       | 83%         |






- Named after Edward Simpson (born 1922)
- A group of sick patients are given the option to try a new drug
- Among those who took the drug, a lower percentage recovered than among those who did not
- However, when we partition by gender, we see that:
  - more men taking the drug recover than do men are not taking the drug, and
  - more women taking the drug recover than do women are not taking the drug!


#### Table 1.1 Results of a study into a new drug, with gender being taken into account

|                      | Drug     |           |             |  | No Drug  |           |             |
|----------------------|----------|-----------|-------------|--|----------|-----------|-------------|
|                      | patients | recovered | % recovered |  | patients | recovered | % recovered |
| Men                  | 87       | 81        | 93%         |  | 270      | 234       | 87%         |
| Women                | 263      | 192       | 73%         |  | 80       | 55        | 69%         |
| <b>Combined data</b> | 350      | 273       | 78%         |  | 350      | 289       | 83%         |

Table 1.2 Results of a study into a new drug, with posttreatment blood pressure taken into account

|                      |          | No Drug   |             |          | Drug      |             |
|----------------------|----------|-----------|-------------|----------|-----------|-------------|
|                      | patients | recovered | % recovered | patients | recovered | % recovered |
| Low BP               | 87       | 81        | 93%         | 270      | 234       | 87%         |
| High BP              | 263      | 192       | 73%         | 80       | 55        | 69%         |
| <b>Combined data</b> | 350      | 273       | 78%         | 350      | 289       | 83%         |





### Simpson's Paradox


- Named after Edward Simpson (born 1922)
- A group of sick patients are given the option to try a new drug
- Among those who took the drug, a lower percentage recovered than among those who did not
- However, when we partition by gender, we see that:
  - more men taking the drug recover than do men are not taking the drug, and
  - more women taking the drug recover than do women are not taking the drug!


#### Table 1.1 Results of a study into a new drug, with gender being taken into account

|               | Drug     |           |             | No Drug  |           |             |  |
|---------------|----------|-----------|-------------|----------|-----------|-------------|--|
|               | patients | recovered | % recovered | patients | recovered | % recovered |  |
| Men           | 87       | 81        | 93%         | 270      | 234       | 87%         |  |
| Women         | 263      | 192       | 73%         | 80       | 55        | 69%         |  |
| Combined data | 350      | 273       | 78%         | 350      | 289       | 83%         |  |

Table 1.2 Results of a study into a new drug, with posttreatment blood pressure taken into account


|                      | No Drug  |           |             |          | Drug      |             |  |  |
|----------------------|----------|-----------|-------------|----------|-----------|-------------|--|--|
|                      | patients | recovered | % recovered | patients | recovered | % recovered |  |  |
| Low BP               | 87       | 81        | 93%         | 270      | 234       | 87%         |  |  |
| High BP              | 263      | 192       | 73%         | 80       | 55        | 69%         |  |  |
| <b>Combined data</b> | 350      | 273       | 78%         | 350      | 289       | 83%         |  |  |





# Healthcare, Medicine and Biology

— past and running research projects @MADLab —





Stella, F. and Amer, Y. (2012), Continuous time Bayesian network classifiers. *Journal of Biomedical Informatics*, 45, 1108–1119.

120 trajectories X 7 movements

6 classes


| Movement id | Description  |
|-------------|--|
| 1           | Abduction-adduction of the upper<br>limb on a frontal plane  |
| 2           | Abduction-adduction of the upper<br>limb on a sagittal plane |
| 3           | External rotation of the forearm                             |
| 4           | Flexion-extension of the elbow                               |
| 5           | Pronation-supination of the forearm                          |
| 6           | Functional activity: eating                                  |
| 7           | Functional activity: combing                                 |

| Class index | Correctness | Speed   | Description                          |
|-------------|-------------|---------|--------------------------------------|
| 1           | Correct     | Slow    | Reference                            |
| 2           | Correct     | Average | Reference                            |
| 3           | Correct     | Fast    | Reference                            |
| 4           | Incorrect   | Average | Movement too small                   |
| 5           | Incorrect   | Average | Typical compensatory action (first)  |
| 6           | Incorrect   | Average | Typical compensatory action (second) |

2 classes

### **Microbial Communities in the Tropical Air Ecosystem**

- Case of Study A mixture of microorganisms is constantly present in the environment surrounding us. The atmosphere is no exception to this observation [1].
- Methodology Structural Causal Models (SCM) learned from partial temporal order and observational data.




### Figure 1: Estimated SCM for Ascomycota.

 E. S. Gusareva, E. Acerbi, K. J. Lau, *et al.*, "Microbial communities in the tropical air ecosystem follow a precise diel cycle," *Proceedings of the National Academy of Sciences*. vol. 116, no. 46, pp. 23299–23308, 2019. Table 1 Performance comparison of CTBNs, DBNs and GC on simulated data for different network dimensions. Organism *E.coli* (top) and *S. cerevisiae* (bottom). The data shown here corresponds to Figure 3


| Method | NETs size | Mean<br>precision | Mean<br>recall | Mean F <sub>1</sub> |
|--------|-----------|-------------------|----------------|---------------------|
|        | 10        | 0.46              | 0.68           | 0.54                |
| CC     | 20        | 0.40              | 0.70           | 0.49                |
| GC     | 50        | 0.24              | 0.82           | 0.37                |
|        | 100       | 0.16              | 0.82           | 0.27                |
| DBNs   | 10        | 0.90              | 0.29           | 0.41                |
|        | 20        | 0.55              | 0.42           | 0.47                |
| CTBNs  | 10        | 0.66              | 0.58           | 0.61                |
|        | 20        | 0.72              | 0.48           | 0.57                |
|        | 50        | 0.53              | 0.57           | 0.54                |
|        | 100       | 0.45              | 0.51           | 0.48                |
| Random | 10        | 0.16              | 0.55           | 0.24                |
|        | 20        | 0.11              | 0.51           | 0.18                |
|        | 50        | 0.03              | 0.49           | 0.06                |
|        | 100       | 0.02              | 0.50           | 0.04                |

| Method | NETs size | Mean<br>precision | Mean<br>recall | Mean F <sub>1</sub> |
|--------|-----------|-------------------|----------------|---------------------|
| GC     | 10        | 0.42              | 0.75           | 0.52                |
|        | 20        | 0.28              | 0.81           | 0.41                |
|        | 50        | 0.22              | 0.78           | 0.34                |
|        | 100       | 0.14              | 0.80           | 0.23                |
| DBNs   | 10        | 0.62              | 0.53           | 0.56                |
|        | 20        | 0.60              | 0.57           | 0.58                |
| CTBNs  | 10        | 0.95              | 0.58           | 0.69                |
|        | 20        | 0.72              | 0.70           | 0.70                |
|        | 50        | 0.64              | 0.56           | 0.59                |
|        | 100       | 0.56              | 0.51           | 0.53                |
| Random | 10        | 0.18              | 0.59           | 0.27                |
|        | 20        | 0.07              | 0.49           | 0.12                |
|        | 50        | 0.05              | 0.50           | 0.08                |
|        | 100       | 0.02              | 0.50           | 0.05                |




Acerbi, E., Vigano, E., Poidinger, M., Mortellaro, A., Zelante, T., & Stella, F. (2016). Continuous time Bayesian networks identify prdm1 as a negative regulator of th17 cell differentiation in humans. Scientific Reports, 6, 23128.

#### Personalized Arterovenous Fistula Management through utility maximization with Influence Diagrams



Bregoli, A., Neri, L., Botler, M., Schumacher, E., Peralta, R., Ponce, P., & Bellocchio, F. (2021). *Personalized Arterovenous Fistula Management through Utility Maximization with Influence Diagram.* In Proceedings of SMARTERCARE@ AI\*IA (pp. 61-66).


### Causal Discovery for Multicentric Study on Endometrial Cancer



Zanga, Alessio, Alice Bernasconi, Peter J.F. Lucas, Hanny Pijnenborg, Casper Reijnen, Marco Scutari and Fabio Stella. *Risk Assessment of Lymph Node Metastases in Endometrial Cancer Patients: A Causal Approach.* Proceedings of HC@AlxIA 2022: 1st AlxIA Workshop on Artificial Intelligence For Healthcare (2022).

Zanga, Alessio, Alice Bernasconi, Peter J.F. Lucas, Hanny Pijnenborg, Casper Reijnen, Marco Scutari and Fabio Stella. *Causal Discovery with Missing Data in a Multicentric Clinical Study*. (In-Press) AIME 2023: 21st International Conference of Artificial Intelligence in Medicine (2023).

### Prediction of Cardiovascular Diseases in Adolescent and Young Breast Cancer Patients







To what extent, with a better understanding of causal mechanisms, it may be possible to identify, predict and explain individual susceptibility to cardiotoxicity prior to starting cancer-related treatments in AYA with BC?

pRedicting cardiOvascular diSeAses iN adolescent and young breast caNcer pAtients (ROSANNA)

### Constraint Based Structure Learning for Continuous Time Bayesian Network






Bregoli, Alessandro, Marco Scutari, and Fabio Stella.

A constraint-based algorithm for the structural learning of continuous-time Bayesian networks. International Journal of Approximate Reasoning 138 (2021): 105-122.

Villa-Blanco, C., Bregoli, A., Bielza, C., Larranaga, P., & Stella, F. (2022, September). *Structure learning algorithms for multidimensional continuous-time Bayesian network classifiers.* In International Conference on Probabilistic Graphical Models (pp. 313-324). PMLR.



Zanga, Alessio, Elif Ozkirimli, and Fabio Stella. *A survey on causal discovery: theory and practice.* International Journal of Approximate Reasoning 151 (2022): 101-129. MG-PerMed - Personalising myasthenia gravis medicine: from "one-fits-all" to patient-specific immunosuppression - ERA-PerMed, 01/03/2023-28/02/2026.





Fig. 1 Schematic representation of the terminal B cells lineage and antibodies involved in the autoimmune attack to the neuromuscular junction. B lymphocytes, plasma cells, and some of the key molecules involved in the immune activation are represented together with available monoclonal antibodies and biologicals targeting CD molecules or receptors. In bold, drugs are effective on different cells. MG, myasthenia gravis; NMJ, neuromuscular junction; MAC, membrane attack complex Data Fusion and Federated Causal Discovery - "Intelligent Ecosystem to improve the governance, the sharing, and the re-use of health Data for Rare Cancers-IDEA4RC" - 2022-2026



# Warning!!! Advertisement!!!

— why do I recommend Bayesian (causal) networks? —

### Seven reasons for choosing Bayesian (causal) networks

- Exploit domain experts' knowledge useful bias
- Missing data management harmful bias
- Effectively combine experimental and observational data
- Data efficient *limited amount of data*
- Model uncertainty
- Interpretable
- Effective decision making address transportability issues

### **Research Team @MadLab**



Alice Bernasconi PhD Candidate in Computer Science (*Istituto Nazionale dei Tumori di Milano*) University of Milano-Bicocca.



Alessandro Bregoli PhD Candidate in Computer Science (Funded by *Fresenius Medical Care*) University of Milano-Bicocca.



Marco Locatelli Master Degree in Computer Science University of Milano-Bicocca.



Alessio Zanga PhD Candidate in Computer Science (Funded by *F. Hoffmann - La Roche SA*) University of Milano-Bicocca.



Niccolò Rocchi 2<sup>nd</sup> year Master student in Data Science Master Degree Student University of Milano-Bicocca.



Marco Scutari PhD Senior Researcher in Bayesian Networks and Graphical Models Istituto Dalle Molle di Studi sull'Intelligenza Artificiale (IDSIA), Lugano (Swiss)




Peter Lucas Professor (Department of Datascience) University of Twente Enschede (Netherlands)



Søren Wengel Mogensen Postdoc Department of Automatic Control, Lund University (Sweden)

### Collaborations

## References



## CAUSAL INFERENCE IN STATISTICS

A Primer

#### Judea Pearl Madelyn Glymour Nicholas P. Jewell



WILEY

DOI:10.1145/3271625

What just happened in artificial intelligence and how it is being misunderstood.

**BY ADNAN DARWICHE** 

## Human-Level Intelligence or Animal-Like Abilities?

"The vision systems of the eagle and the snake outperform everything that we can make in the laboratory, but snakes and eagles cannot build an eyeglass or a telescope or a microscope." JUDEA PEARL WINNER OF THE TURING AWARD

AND DANA MACKENZIE

# THE BOOK OF WHY



THE NEW SCIENCE OF CAUSE AND EFFECT